MARKET WIREStockInvest.us • 18h ago
Skye Bioscience Stock Price Forecast. Should You Buy SKYE?StockInvest.us report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
Why SKYE Stock dropped -2.29% Today — RQD Quant Desk Flash
$1.28 -2.29% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $1.27
Skye Bioscience Inc. (SKYE) carries a Roarable Rating of E (Strong Sell) with 34/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $5.7M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on SKYE Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is SKYE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-03, Skye Bioscience Inc. (NASDAQ: SKYE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.28 (-2.29% 1D, market cap $5.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SKYE ranks #657 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does SKYE compare to ACXP and ALZN in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SKYE carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACXP (Acurx Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M) and ALZN (Alzamend Neuro Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M). Among the 5-stock peer group, SKYE leads on earnings multiple (N/A) while SKYE leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for SKYE?
▼
Per SKYE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001516551), Skye Bioscience Inc. generated $0 in revenue, -$55.9M in net income, and -$43.1M in free cash flow against $28.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $1.27 (-0.60%)🧬 Disciplined Float (+0.72% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (34/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-8.7% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D
Each axis scored 0–20
12M PRICE TARGET CONE-10.9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SKYE)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (34/100 Composite)
🔍 WHY SKYE SCORES 34/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (29% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Cash Engine Quality+8/20 pts (24% of score)
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin
▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)
Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$1.53+5.9% Next Q
42
Q2 (-2Q)Grade E$1.62-10.5% Next Q
39
Q3 (-1Q)Grade E$1.45-11.7% Next Q
37
CurrentGrade E$1.28-8.7% Hist 90D α
34
Trajectory: D (42) → E (34)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a SKYE Turnaround Squeeze
While SKYE currently carries a cautious 34/100 (E) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.69) and Max Pain ($1.34) forces dealer call-delta covering toward $13.44.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Disciplined Float (+0.72% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $SKYE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “SKYE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why SKYE Stock dropped -2.29% Today — RQD Quant Desk Flash
Skye Bioscience Inc. (SKYE) dropped -2.29% to $1.28, trading at 2% of its 52-week range ($1.25 – $12.8). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 2% of its 52-week range ($1.25 – $12.8) with RSI-14 at 32 (OVERSOLD (<32)).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $1.28 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live SKYE Headlines & Catalysts
MARKET WIREMoomoo • 21h ago
SKYE BIOSCIENCE INC (SKYE) Stock Forum and DiscussionMoomoo report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
Two holders report shared voting power over the same 263,560 Skye Bioscience (SKYE) shares.Stock Titan report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingView • 1d ago
SKYE Q3'26 Earnings: revenue estimate is 0 USDTradingView report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo! Finance Canada • 1d ago
Kazia Therapeutics Limited (KZIA) Seasonal Returns Chart - Yahoo FinanceYahoo! Finance Canada report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 1d ago
Most Active Stocks Today: U.S. MarketTradingKey report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
CATALYSTTradingKey • 1d ago
Top U.S. Stock Gainers: Biggest Price IncreasesTradingKey report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
MARKET WIRETradingKey • 1d ago
Complete U.S. Stocks List: Prices, Performance and Key DataTradingKey report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SKYE)
- ✓Walkthrough of SKYE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
SKYE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -81.61%🛡️ HOLDING TREND SUPPORT
2026-11-03O $1.31H $1.31L $1.28C $1.28VOL 40.6K
RES: $6.64SUP: $1.22SMA50: $1.69SMA200: $4.79
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
SKYE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on SKYE today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for SKYE. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for SKYE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SKYE)
Health Care Rank #657 of 1016
⚔️ ACXP vs SKYE Full Matrix →
1. Head-to-Head Health Care Peer Comparison (SKYE vs. ACXP, ALZN, BGMS, LGVN)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Skye Bioscience Inc. (SKYE) ranks #657 by composite RQD confidence (34/100, grade E) and #931 by equity capitalization ($5.7M). Within this direct 5-issuer industry benchmark cohort, SKYE leads on earnings valuation at N/A trailing P/E, while SKYE leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. BGMS currently holds the highest overall quantitative score in the immediate peer group at 38/100 (D-) compared with SKYE at 34/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SKYE
ACTIVE
Skye Bioscience Inc. | E | 34/100 | — | — | -35.0% | -2.29% | $5.7M | Benchmark Subject |
| ACXP Acurx Pharmaceuticals Inc. | E | 33/100 | — | — | -35.0% | -2.80% | $5.8M | /acxp-vs-skye → |
| ALZN Alzamend Neuro Inc. | E | 34/100 | — | — | -35.0% | -0.82% | $5.8M | /alzn-vs-skye → |
| BGMS Bio Green Med Solution Inc. | D- | 38/100 | — | — | -35.0% | +8.43% | $6.0M | /bgms-vs-skye → |
| LGVN Longeveron Inc. (Class A) | E | 27/100 | — | 67.0% | -35.0% | -4.57% | $5.3M | /lgvn-vs-skye → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001516551In its most recent audited fiscal period (FY2025, filed 2025-12-31), Skye Bioscience Inc. (SKYE) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$55.9M, operating cash flow of -$43.1M, and free cash flow of -$43.1M (-60.5% YoY). On the balance sheet, SKYE closed FY2025 with $28.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$55.9M | -$43.1M | -$43.1M | $28.3M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$26.6M | -$25.2M | -$26.8M | $72.8M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$37.6M | -$14.0M | -$14.0M | — | — |
3. SKYE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs SKYE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-03, Skye Bioscience Inc. (NASDAQ: SKYE) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 34/100 at a spot price of $1.28 (-2.29% 1D, market cap $5.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 3/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SKYE ranks #657 in composite RQD confidence.
How does SKYE compare to ACXP and ALZN in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SKYE carries a Roarable E (34/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, ACXP (Acurx Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M) and ALZN (Alzamend Neuro Inc.) posts a E grade (34/100 RQD, P/E N/A, ROIC -35.0%, cap $5.8M). Among the 5-stock peer group, SKYE leads on earnings multiple (N/A) while SKYE leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for SKYE?
Per SKYE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001516551), Skye Bioscience Inc. generated $0 in revenue, -$55.9M in net income, and -$43.1M in free cash flow against $28.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is SKYE trading relative to its 50-day, 200-day, and 52-week technical levels?
SKYE last traded at $1.28 (-2.29% on volume of 40,559 shares), positioning the stock -24.26% below its 50-day simple moving average ($1.69) and -73.28% below its 200-day simple moving average ($4.79). Across its 52-week range of $1.25 to $12.80, SKYE sits at the 0.3% percentile with a 14-day RSI of 32.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($1.12 to $1.44).
SKYE Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is SKYE stock moving today?
Why SKYE Stock dropped -2.29% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 34/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
SKYE — Skye Bioscience Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:52:58Z
Roarable Rating Brief: What This Means to a Prospective Investor
The Roarable RQD rating assigns SKYE a score of 35 out of 100, a letter grade of D-, and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow," per the Roarable RQD rating.
Across the five pillars:
- Fundamental Cash Engine: 8 / 20. The pillar reflects ROIC of -35% and an FCF yield of 0%. For a prospective investor, this means the business is currently consuming capital rather than generating a return on it. The absence of positive cash generation removes the usual valuation anchor, so the share price rests on expectations of future outcomes that the source data does not quantify.
- Whale 13F Flow: 3 / 20. The pillar captures institutional accumulation and options positioning, and it scores near the bottom of its range. The source data contains no holder detail (see the Analyst View section), so the low score signals weak or absent institutional sponsorship rather than a specific selling event.
- Insider Conviction: 5 / 20. The pillar reflects SEC Form 4 and Congressional PTR cluster flow. A low score here means the source data does not show insider activity that would indicate management confidence in the shares.
- Macro Regime Fit: 9 / 20. The pillar reflects a beta of 1.0 and sector sensitivity. A beta of 1.0 indicates market-level volatility in the source data, but the score is held down by the company's sector exposure and its lack of revenue.
- Forensic Balance Sheet: 10 / 20. The pillar reflects an Altman Z-Score of 2.5, a Piotroski F-Score of 2/9, and a Debt/Equity ratio of 0.5. The Piotroski reading of 2/9 is weak, and the balance sheet data shows cash declining from $68.4M to $5.9M across the reported fiscal years.
Taken together, the pillars describe a company with a weak cash-generation profile, limited institutional and insider support in the source data, and a balance sheet under visible strain. The score suggests that a prospective investor evaluating SKYE today would be weighing a highly speculative equity against a shrinking cash position. Upside would depend on developments outside the reported financials, which the source data does not describe. The valuation tradeoff is stark: with no earnings, no revenue, and negative ROIC, conventional multiples are unavailable, leaving price as the only observable signal.
Business
Skye Bioscience Inc. is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry, per the profile. The source data does not describe its products, customers, or revenue model. The FY 2025 and FY 2024 financials report revenue of $0.0M in each year, so the source data shows no reported revenue in the periods covered.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-58.2M | $-55.9M | N/A | $-43.1M | $5.9M | N/A |
| FY 2024 | $0.0M | $-30.2M | $-26.6M | N/A | $-26.8M | $68.4M | N/A |
| FY 2023 | $0.0M | $-34.7M | $-37.6M | N/A | $-14.0M | N/A | N/A |
Per the SEC financials, the company reported operating losses in all three periods, with the FY 2025 operating loss of $-58.2M the largest in the table. Gross, operating, and net margins are each 0% per the market data, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2/9, per the Roarable RQD rating's forensic balance sheet pillar. Reported cash fell from $68.4M in FY 2024 to $5.9M in FY 2025, and debt is listed as N/A in the reported periods.
Recent Catalysts & News Wire Analysis
The news feed contains six items, all rated YELLOW and labeled MARKET WIRE:
- StockInvest.us published a stock price forecast and buy-or-sell commentary on SKYE.
- Moomoo published a stock forum and discussion item.
- Stock Titan reported that two holders report shared voting power over the same 263,560 Skye Bioscience (SKYE) shares.
- TradingView published an item titled around the SKYE Q3'26 earnings with a revenue estimate of 0 USD.
- Yahoo! Finance Canada published a seasonal returns chart for Kazia Therapeutics Limited (KZIA), a different issuer.
- TradingKey published a most-active-stocks item covering the U.S. market.
Risk watch items from the feed are the reported shared voting power over 263,560 shares, and the 0 USD revenue estimate attached to the upcoming quarter. The KZIA item is unrelated to SKYE and carries no company-specific information. The Butterfly supply-chain graph reports no supply-chain links and no proprietary signals.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. The source data therefore identifies no upstream suppliers, downstream customers, or sector-correlated counterparties for SKYE. Sector and industry classification (Health Care; Biotechnology: Pharmaceutical Preparations) are the only sector-level context available. An investor looking for second-order ripples should note that the source data does not map any dependencies, and any such analysis would require information not contained in this dataset.
Open Questions
- What products or development programs does the company have, and what regulatory milestones are tied to them? The source data does not describe the business beyond its sector classification.
- What is the source of the reported decline in cash from $68.4M to $5.9M, and what is the company's runway at the FY 2025 burn rate of $-43.1M in free cash flow?
- What is the debt position? The debt line is N/A across all reported periods, and the Debt/Equity ratio of 0.5 cannot be traced to its components in the source data.
- Who are the two holders reporting shared voting power over 263,560 shares, and what is the nature of that arrangement?
- What explains the 52-week price range of $1.25 to $12.96, and what drove the -13.82% change in the most recent session?
SKYE Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Skye Bioscience Inc. (SKYE) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE StockInvest.us • 18h ago
Skye Bioscience Stock Price Forecast. Should You Buy SKYE? StockInvest.us report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Moomoo • 21h ago
SKYE BIOSCIENCE INC (SKYE) Stock Forum and Discussion Moomoo report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
Two holders report shared voting power over the same 263,560 Skye Bioscience (SKYE) shares. Stock Titan report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 1d ago
SKYE Q3'26 Earnings: revenue estimate is 0 USD TradingView report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago
Kazia Therapeutics Limited (KZIA) Seasonal Returns Chart - Yahoo Finance Yahoo! Finance Canada report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 1d ago
Most Active Stocks Today: U.S. Market TradingKey report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
🟢 CATALYST TradingKey • 1d ago
Top U.S. Stock Gainers: Biggest Price Increases TradingKey report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingKey • 1d ago
Complete U.S. Stocks List: Prices, Performance and Key Data TradingKey report covering Skye Bioscience Inc. (SKYE) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
SKYE Bull vs. Bear Conversation Board — What's Your Call at $1.28?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SKYE 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $1.15 (-12.2%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is SKYE (D- • RQD 35/100) a Buy at $1.31?
Welcome to the SKYE (Skye Bioscience Inc.) Roar Pit. Current RQD Composite is 35/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Pharmaceutical Preparations. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
FO ForensicBear Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $1.02 (-22.1%)
Spot @ $1.31 Pump the brakes on SKYE — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on SKYE, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Skye Bioscience Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH
🎯 Target: $1.57 (+19.8%)
Spot @ $1.31 SKYE cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on SKYE, the market is fixating on short-term headline noise in Biotechnology: Pharmaceutical Preparations and ignoring the balance sheet and cash flow trajectory. At $1.31 (52-wk range $1.25 - $12.96), any beat on forward guidance forces shorts and underweight funds to chase.